AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
AGIOS PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$34.90+3.58 (+11.43%)
Close on Oct 19, 2026
- Market cap
- $2.08B
- P/E (TTM)
- –
- Dividend yield
- –
Agios Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Agios Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $2.08B | $197.05M |
| Enterprise Value | $1.08B | $106.56M |
| PS Ratio | 21.19 | 3.93 |
| PB Ratio | 2.03 | 2.14 |
| P/TBV Ratio | 2.03 | 2.46 |
Enterprise value
| Measure | Agios Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 11.02 | 2.69 |
Income (trailing twelve months)
| Measure | Agios Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $98.34M | $57.94M |
| Gross Profit | $90.47M | $90.47M |
| Operating Income | -$459.02M | -$21.44M |
| Net Income | -$411.29M | -$22.46M |
| EBITDA | -$459.02M | -$16.91M |
| EPS (Diluted) | -$7.01 | -$0.83 |
Margins
| Measure | Agios Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 92.0% | 52.3% |
| Operating Margin | -466.8% | -44.5% |
| Profit Margin | -418.2% | -39.2% |
| EBITDA Margin | -466.8% | -31.3% |
| FCF Margin | -371.4% | -8.85% |
Returns
| Measure | Agios Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -34.3% | -53.1% |
| Return on Assets (ROA) | -31.9% | -41.0% |
| Return on Invested Capital (ROIC) | -758.8% | -32.0% |
| Return on Capital Employed (ROCE) | -44.2% | -37.8% |
Growth
| Measure | Agios Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 140.6% | 6.01% |
| Net Income Growth (YoY) | -163.3% | -37.7% |
| EPS Growth (YoY) | -163.2% | -29.2% |
| Revenue Growth (3Y CAGR) | 56.0% | 2.25% |
Balance sheet
| Measure | Agios Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.00B | $62.42M |
| Net Cash (Debt) | $1.00B | $15.68M |
| Net Cash Per Share | $16.75 | $0.65 |
| Equity (Book Value) | $1.03B | $48.79M |
| Book Value Per Share | $17.19 | $1.36 |
| Tangible Book Value | $1.03B | $23.06M |
| Working Capital | $647.45M | $75.77M |
Financial position
| Measure | Agios Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 10.22 | 3.30 |
| Quick Ratio | 14.24 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Agios Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$360.60M | -$12.35M |
| Capital Expenditures | -$4.66M | -$1.06M |
| Free Cash Flow | -$365.25M | -$20.28M |
| FCF Per Share | -$6.12 | -$0.41 |
Efficiency
| Measure | Agios Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.08 | 0.38 |
| Inventory Turnover | 0.24 | 2.67 |
| Revenue Per Employee | $182.45K | $398.96K |
| Profits Per Employee | -$763.05K | -$732.08K |
| Employee Count | 539 | 73 |
Dividends and yields
| Measure | Agios Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -19.7% | -21.2% |
| FCF Yield | -17.5% | -7.64% |
Shares
| Measure | Agios Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 59,701,900 | 59,128,900 |
| Shares Change (YoY) | 0.91% | 11.1% |
| Shares Change (QoQ) | 0.44% | 0.54% |
| Float | 59,033,300 | 48,744,500 |
| Shares Held by Insiders | 1.12% | 11.8% |
| Shares Held by Institutions | 110.7% | 59.4% |
Scores
| Measure | Agios Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 13.63 | 0.10 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Agios Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.